A. Ravaud Et Al. , "Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.31, Illinois, United States Of America, 2013
Ravaud, A. Et Al. 2013. Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Ravaud, A., Barrios, C. H., Alekseev, B. Y., Tay, M. H., Agarwala, S. S., Yalcin, S., ... Lin, C.(2013). Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results . 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Ravaud, Alain Et Al. "Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2013
Ravaud, Alain Et Al. "Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2013
Ravaud, A. Et Al. (2013) . "Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Alain Ravaud Et Al. }, title={Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon alpha-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results}, congress name={49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2013}}